• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Neoadjuvant chemotherapy for muscle-invasive bladder cancer with variant histology and/or divergent differentiation.

作者信息

Tashiro Kojiro, Urabe Fumihiko, Kimura Takahiro

机构信息

Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.

Department of Urology, The Jikei University School of Medicine Katsushika Medical Center, Tokyo, Japan.

出版信息

Transl Androl Urol. 2025 May 30;14(5):1155-1157. doi: 10.21037/tau-2025-13. Epub 2025 May 27.

DOI:10.21037/tau-2025-13
PMID:40529027
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12169977/
Abstract
摘要

相似文献

1
Neoadjuvant chemotherapy for muscle-invasive bladder cancer with variant histology and/or divergent differentiation.针对具有组织学变异和/或分化异常的肌层浸润性膀胱癌的新辅助化疗。
Transl Androl Urol. 2025 May 30;14(5):1155-1157. doi: 10.21037/tau-2025-13. Epub 2025 May 27.
2
Impact of Divergent Differentiation and/or Histological Subtype of Urothelial Carcinoma on Patient Outcomes in the GETUG-AFU V05 VESPER Trial.尿路上皮癌的分化差异和/或组织学亚型对GETUG-AFU V05 VESPER试验中患者预后的影响
J Urol. 2024 Apr;211(4):564-574. doi: 10.1097/JU.0000000000003836. Epub 2023 Dec 28.
3
Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy.膀胱切除术联合或不联合新辅助化疗治疗膀胱癌的病理和生存结果与变异组织学相关。
J Urol. 2021 Jan;205(1):100-108. doi: 10.1097/JU.0000000000001325. Epub 2020 Aug 12.
4
Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer.新辅助化疗治疗变异型组织学肌层浸润性膀胱癌的降期病理与生存结局。
J Urol. 2021 Oct;206(4):924-932. doi: 10.1097/JU.0000000000001855. Epub 2021 May 25.
5
Neoadjuvant chemotherapy for muscle-invasive bladder cancer: does variant histology matter?新辅助化疗治疗肌层浸润性膀胱癌：肿瘤异质性有影响吗？
Int Urol Nephrol. 2022 Dec;54(12):3163-3169. doi: 10.1007/s11255-022-03358-3. Epub 2022 Sep 5.
6
The effect of neoadjuvant chemotherapy among patients undergoing radical cystectomy for variant histology bladder cancer: A systematic review.新辅助化疗对组织学类型变异的膀胱癌患者行根治性膀胱切除术的疗效：一项系统评价。
Arab J Urol. 2021 Nov 7;20(1):1-13. doi: 10.1080/2090598X.2021.1994230. eCollection 2022.
7
Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.PURE-01的更新结果：新辅助派姆单抗在组织学变异的肌层浸润性膀胱癌患者中的初步活性
Eur Urol. 2020 Apr;77(4):439-446. doi: 10.1016/j.eururo.2019.10.026. Epub 2019 Nov 8.
8
MRI-based automated machine learning model for preoperative identification of variant histology in muscle-invasive bladder carcinoma.基于 MRI 的自动化机器学习模型用于术前识别肌层浸润性膀胱癌的变异组织学。
Eur Radiol. 2024 Mar;34(3):1804-1815. doi: 10.1007/s00330-023-10137-w. Epub 2023 Sep 2.
9
Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.肌层浸润性膀胱癌新辅助化疗完全病理缓解（pT0）的预测因素
Clin Genitourin Cancer. 2016 Feb;14(1):e59-65. doi: 10.1016/j.clgc.2015.09.013. Epub 2015 Oct 3.
10
Trends in the use of neoadjuvant chemotherapy for bladder cancer with nonurothelial variant histology: An analysis of the National Cancer Database.非尿路上皮变异组织学类型膀胱癌新辅助化疗的使用趋势：一项基于国家癌症数据库的分析
Indian J Urol. 2019 Oct-Dec;35(4):291-298. doi: 10.4103/iju.IJU_142_19.

本文引用的文献

1
Impact of systemic therapy on clinical T1 small-cell neuroendocrine carcinoma of the bladder.全身治疗对膀胱临床 T1 小细胞神经内分泌癌的影响。
ESMO Open. 2024 Nov;9(11):103964. doi: 10.1016/j.esmoop.2024.103964. Epub 2024 Oct 30.
2
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.可手术膀胱癌新辅助化疗联合围手术期 durvalumab 治疗。
N Engl J Med. 2024 Nov 14;391(19):1773-1786. doi: 10.1056/NEJMoa2408154. Epub 2024 Sep 15.
3
Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer.
免疫特征与肌层浸润性膀胱癌新辅助化疗免疫治疗的反应相关。
Nat Commun. 2024 May 24;15(1):4448. doi: 10.1038/s41467-024-48480-1.
4
Impact of Divergent Differentiation and/or Histological Subtype of Urothelial Carcinoma on Patient Outcomes in the GETUG-AFU V05 VESPER Trial.尿路上皮癌的分化差异和/或组织学亚型对GETUG-AFU V05 VESPER试验中患者预后的影响
J Urol. 2024 Apr;211(4):564-574. doi: 10.1097/JU.0000000000003836. Epub 2023 Dec 28.
5
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.肌层浸润性膀胱癌中围手术期密集剂量甲氨蝶呤、长春碱、阿霉素和顺铂（VESPER）：一项开放标签、随机、3 期研究的 5 年生存终点。
Lancet Oncol. 2024 Feb;25(2):255-264. doi: 10.1016/S1470-2045(23)00587-9. Epub 2023 Dec 21.
6
Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.吉西他滨和顺铂分剂量联合帕博利珠单抗作为新辅助治疗在肌层浸润性膀胱癌患者根治性膀胱切除术前的 II 期研究。
J Clin Oncol. 2021 Oct 1;39(28):3140-3148. doi: 10.1200/JCO.21.01003. Epub 2021 Aug 24.
7
Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer.新辅助化疗治疗变异型组织学肌层浸润性膀胱癌的降期病理与生存结局。
J Urol. 2021 Oct;206(4):924-932. doi: 10.1097/JU.0000000000001855. Epub 2021 May 25.
8
Urothelial carcinoma: variant histology, molecular subtyping, and immunophenotyping significant for treatment outcomes.尿路上皮癌：具有治疗结局意义的变异组织学、分子亚型和免疫表型。
Pathology. 2021 Jan;53(1):56-66. doi: 10.1016/j.pathol.2020.09.004. Epub 2020 Oct 16.
9
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines Committees.EAU-ESMO 共识声明：晚期和变异型膀胱癌的管理——一项国际协作多方利益相关者的努力：在 EAU-ESMO 指南委员会的支持下。
Eur Urol. 2020 Feb;77(2):223-250. doi: 10.1016/j.eururo.2019.09.035. Epub 2019 Nov 19.
10
Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.帕博利珠单抗作为肌层浸润性尿路上皮膀胱癌根治性切除术的新辅助治疗（PURE-01）：一项开放标签、单臂、Ⅱ期研究。
J Clin Oncol. 2018 Dec 1;36(34):3353-3360. doi: 10.1200/JCO.18.01148. Epub 2018 Oct 20.